吉林敖东：2025年半年度净利润增长138.44% 连续两年中期分红回报股东

Core Viewpoint - Jilin Aodong reported a significant increase in net profit for the first half of 2025, showcasing strong profitability and growth resilience despite a decline in operating revenue [1][2] Financial Performance - The company achieved a net profit of 1.282 billion yuan, a year-on-year increase of 138.44% [1] - Total assets reached 34.151 billion yuan, up 3.48% year-on-year [1] - Net assets attributable to shareholders increased by 3.21% to 29.960 billion yuan [1] - The asset-liability ratio remained low at 11.54%, indicating a robust financial structure [1] - Operating revenue was 1.126 billion yuan, down 20.21% year-on-year [1] Dividend and Share Buyback - Jilin Aodong proposed a cash dividend of 2.00 yuan per 10 shares, totaling an estimated cash distribution of 234 million yuan [1] - The company has implemented mid-year dividends for two consecutive years since 2024, reflecting its commitment to shareholder returns [1] - In the first half of 2025, the company repurchased shares worth 120 million yuan, bringing the total cash distribution and share buyback to 354 million yuan, which is 27.66% of the net profit attributable to shareholders [1] Shareholder Return Commitment - Jilin Aodong has consistently returned profits to shareholders, having distributed a total of 4.505 billion yuan since its listing, with 17 consecutive years of cash dividends [2] - The company emphasized that mid-year dividends enhance shareholder confidence and signal stable operations and ample cash flow [2] - As a diversified enterprise group driven by "pharmaceutical health + financial capital," Jilin Aodong's performance and dividend policy reflect its commitment to stable operations and shareholder returns [2]